SG11201908578YA - Fc-optimized anti-cd25 for tumour specific cell depletion - Google Patents
Fc-optimized anti-cd25 for tumour specific cell depletionInfo
- Publication number
- SG11201908578YA SG11201908578YA SG11201908578YA SG11201908578YA SG 11201908578Y A SG11201908578Y A SG 11201908578YA SG 11201908578Y A SG11201908578Y A SG 11201908578YA SG 11201908578Y A SG11201908578Y A SG 11201908578YA
- Authority
- SG
- Singapore
- Prior art keywords
- stevenage
- london
- tusk
- catalyst
- building
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 241000581479 Apodichthys Species 0.000 abstract 2
- 241001609030 Brosme brosme Species 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000002023 wood Substances 0.000 abstract 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 1
- 241000451147 Lacon Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000003782 apoptosis assay Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIPO I PCT omit VIII °nolo omioom Homo oimIE (10) International Publication Number WO 2018/167104 Al 1-1 71. O 1-1 N 1-1 00 1-1 O (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) CO7K 14/55 (2006.01) (21) International Application Number: PCT/EP2018/056312 (22) International Filing Date: 13 March 2018 (13.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17161717.8 17 March 2017 (17.03.2017) EP 1710879.6 06 July 2017 (06.07.2017) GB 1714429.6 07 September 2017 (07.09.2017) GB (71) Applicants: TUSK THERAPEUTICS LTD [GB/GB]; Stevenage Bioscience Catalyst, Accelerator Building, Gun- nels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). CANCER RESEARCH TECHNOLOGY LIMIT- ED [GB/GB]; Angel Building, 407 St John Street, London EC1V 4AD (GB). (72) Inventors: GOUBIER, Anne; c/o Tusk Therapeutics Lim- ited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). MERCHIERS, Pascal; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hert- fordshire SG1 2FX (GB). SALIMU, Josephine; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gun- nels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). GOYENECHEA, Beatriz; c/o Tusk Therapeutics Limit- ed, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). MOULDER, Kevin; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hertford- shire SG1 2FX (GB). QUEZADA, Sergio; c/o Cancer Re- search Technology Limited, Angel Building, 407 St John Street, London Greater London EC1V 4AD (GB). PEG- GS, Karl; c/o Cancer Research Technology Limited, Angel Building, 407 St John Street, London Greater London EC1V 4AD (GB). VARGAS, Fred Arce; c/o Cancer Research Technology Limited, Angel Building, 407 St John Street, London Greater London EC1V 4AD (GB). SOLOMON, Isabelle; c/o Cancer Research Technology Limited, Angel Building, 407 St John Street, London Greater London EC1V 4AD (GB). (74) Agent: LEONARD, Thomas Charles; Kilburn & Strode LLP, Lacon London, 84 Theobalds Road, London London WC1X 8NL (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: FC-OPTIMIZED ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION (57) : The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2 - CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17161717 | 2017-03-17 | ||
| GBGB1710879.6A GB201710879D0 (en) | 2017-07-06 | 2017-07-06 | Methods and compounds for tumour-specific cell depletion |
| GBGB1714429.6A GB201714429D0 (en) | 2017-09-07 | 2017-09-07 | Compounds and methods for tumour-specific cell depletion |
| PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908578YA true SG11201908578YA (en) | 2019-10-30 |
Family
ID=61655786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908578Y SG11201908578YA (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11879014B2 (en) |
| EP (1) | EP3596123B1 (en) |
| JP (2) | JP2020514363A (en) |
| KR (1) | KR20190130137A (en) |
| CN (1) | CN110869388A (en) |
| AU (1) | AU2018233976A1 (en) |
| BR (1) | BR112019017017A2 (en) |
| CA (1) | CA3056506A1 (en) |
| CL (1) | CL2019002624A1 (en) |
| CR (1) | CR20190477A (en) |
| DK (1) | DK3596123T3 (en) |
| FI (1) | FI3596123T3 (en) |
| IL (1) | IL269081A (en) |
| LT (1) | LT3596123T (en) |
| MX (1) | MX2019010974A (en) |
| PE (1) | PE20191812A1 (en) |
| RS (1) | RS65351B1 (en) |
| SG (1) | SG11201908578YA (en) |
| SI (1) | SI3596123T1 (en) |
| WO (1) | WO2018167104A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US11873341B2 (en) * | 2018-03-13 | 2024-01-16 | Tusk Therapeutics Ltd. | Anti-CD25 for tumour specific cell depletion |
| WO2020102603A1 (en) * | 2018-11-14 | 2020-05-22 | Rubryc Therapeutics, Inc. | Engineered cd25 polypeptides and uses thereof |
| WO2020102591A1 (en) * | 2018-11-14 | 2020-05-22 | Rubryc Therapeutics, Inc. | Cd25 antibodies |
| JP2022538733A (en) * | 2019-05-20 | 2022-09-06 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） | Novel anti-CD25 antibody |
| KR20220007120A (en) * | 2019-06-10 | 2022-01-18 | 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 | Anti-CD25 Antibodies and Applications thereof |
| CA3179937A1 (en) | 2020-04-10 | 2021-10-14 | Rakuten Medical, Inc. | Phthalocyanine dye compounds, conjugates and methods of use thereof |
| US20230174670A1 (en) | 2020-05-14 | 2023-06-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| KR20230118108A (en) * | 2020-11-20 | 2023-08-10 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Anti-CD25 antibody |
| EP4247496A1 (en) * | 2020-11-20 | 2023-09-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Anti-cd25 antibodies |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2022182483A1 (en) * | 2021-02-02 | 2022-09-01 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| MX2023010002A (en) | 2021-03-01 | 2023-09-06 | Hoffmann La Roche | Novel biomarkers and uses thereof. |
| WO2023031403A1 (en) | 2021-09-02 | 2023-03-09 | F. Hoffmann-La Roche Ag | Antibodies for the treatment of aml |
| WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
| CN115181182B (en) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | Humanized anti-CD 25 single domain antibody and application thereof |
| WO2024006965A1 (en) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
| WO2024006961A1 (en) | 2022-07-01 | 2024-01-04 | Neoleukin Therapeutics, Inc. | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN116087499B (en) * | 2023-02-20 | 2023-10-31 | 深圳裕康医学检验实验室 | Staining method and kit for cancer samples |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH05244982A (en) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | Humanized b-b10 |
| KR101329843B1 (en) | 2002-11-15 | 2013-11-14 | 젠맵 에이/에스 | Human monoclonal antibodies against cd25 |
| US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| WO2008003473A2 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| PT2059535E (en) | 2006-08-18 | 2014-01-29 | Novartis Ag | Prlr-specific antibody and uses thereof |
| RU2391401C2 (en) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | METHOD OF OBTAINING POPULATION OF HUMAN CD4+CD25+Foxp3+ T-LYMPHOCYTES ex vivo, DISEASE TREATMENT METHOD |
| DK2356270T3 (en) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| MY160680A (en) | 2009-09-22 | 2017-03-15 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
| AR079944A1 (en) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT |
| EP2595657A4 (en) | 2010-07-22 | 2015-09-23 | Univ California | Anti-tumor antigen antibodies and methods of use |
| CN105377892A (en) | 2013-03-15 | 2016-03-02 | 艾伯维生物技术有限公司 | Anti-CD25 antibodies and their uses |
| WO2014145907A1 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Targeting t cells with heterodimeric proteins |
| EP2970489A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Biotechnology Ltd | Anti-cd25 antibodies and their uses |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CN109476739A (en) | 2016-04-07 | 2019-03-15 | 癌症研究技术有限公司 | Anti- CD25 FC γ receptor bispecific antibody for tumor specific cell abatement |
| SG11201903882VA (en) | 2016-11-08 | 2019-05-30 | Delinia Inc | Il-2 variants for the treatment of autoimmune diseases |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| MX2020008770A (en) | 2018-03-13 | 2020-10-08 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion. |
-
2018
- 2018-03-03 US US16/494,962 patent/US11879014B2/en active Active
- 2018-03-13 MX MX2019010974A patent/MX2019010974A/en unknown
- 2018-03-13 RS RS20240376A patent/RS65351B1/en unknown
- 2018-03-13 CA CA3056506A patent/CA3056506A1/en active Pending
- 2018-03-13 DK DK18711313.9T patent/DK3596123T3/en active
- 2018-03-13 LT LTEPPCT/EP2018/056312T patent/LT3596123T/en unknown
- 2018-03-13 AU AU2018233976A patent/AU2018233976A1/en active Pending
- 2018-03-13 SG SG11201908578Y patent/SG11201908578YA/en unknown
- 2018-03-13 BR BR112019017017A patent/BR112019017017A2/en unknown
- 2018-03-13 EP EP18711313.9A patent/EP3596123B1/en active Active
- 2018-03-13 CN CN201880018976.8A patent/CN110869388A/en active Pending
- 2018-03-13 PE PE2019001847A patent/PE20191812A1/en unknown
- 2018-03-13 WO PCT/EP2018/056312 patent/WO2018167104A1/en active Application Filing
- 2018-03-13 CR CR20190477A patent/CR20190477A/en unknown
- 2018-03-13 FI FIEP18711313.9T patent/FI3596123T3/en active
- 2018-03-13 SI SI201831085T patent/SI3596123T1/en unknown
- 2018-03-13 JP JP2019550705A patent/JP2020514363A/en active Pending
- 2018-03-13 KR KR1020197030283A patent/KR20190130137A/en not_active Application Discontinuation
-
2019
- 2019-09-02 IL IL26908119A patent/IL269081A/en unknown
- 2019-09-13 CL CL2019002624A patent/CL2019002624A1/en unknown
-
2024
- 2024-01-25 JP JP2024009215A patent/JP2024050684A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3596123B1 (en) | 2024-01-10 |
| AU2018233976A1 (en) | 2019-10-31 |
| CN110869388A (en) | 2020-03-06 |
| WO2018167104A1 (en) | 2018-09-20 |
| PE20191812A1 (en) | 2019-12-26 |
| BR112019017017A2 (en) | 2020-04-14 |
| MX2019010974A (en) | 2020-08-03 |
| LT3596123T (en) | 2024-03-25 |
| JP2024050684A (en) | 2024-04-10 |
| US11879014B2 (en) | 2024-01-23 |
| IL269081A (en) | 2019-11-28 |
| FI3596123T3 (en) | 2024-04-17 |
| DK3596123T3 (en) | 2024-02-26 |
| CL2019002624A1 (en) | 2020-04-03 |
| JP2020514363A (en) | 2020-05-21 |
| KR20190130137A (en) | 2019-11-21 |
| CR20190477A (en) | 2020-01-07 |
| EP3596123A1 (en) | 2020-01-22 |
| SI3596123T1 (en) | 2024-05-31 |
| US20200010554A1 (en) | 2020-01-09 |
| RS65351B1 (en) | 2024-04-30 |
| CA3056506A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908578YA (en) | Fc-optimized anti-cd25 for tumour specific cell depletion | |
| SG11201901715UA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201900028VA (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| SG11201805136TA (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
| SG11201910143TA (en) | Combination of a cell therapy and an immunomodulatory compound | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201900085TA (en) | Modified ligand-gated ion channels and methods of use | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201908980PA (en) | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells | |
| SG11201805771XA (en) | Systems and methods for preparation of platelets | |
| SG11201810801QA (en) | Brain delivery protein |